The Patient Protection and Affordable Care Act (PPACA) established the Prevention and Public Health Fund (PPHF), and by law, the Fund must be used to provide for expanded and sustained national investment in preventative public health programs to improve health, enhance healthcare quality, and help restrain the rate of growth in private and public healthcare costs.
First authorized in 2010, to date the Fund has invested in a broad range of evidence-based activities from the federal to state to local community levels, including clinical and community prevention activities such as chronic disease management initiatives, research, public health infrastructure operations, initiatives to address college suicides, smoking and tobacco prevention, surveillance and tracking, programs for low-income mothers, and public health workforce training. (More)
Natural and manmade disasters have ravaged the United States and the world extensively during the past decade, and they have put healthcare providers - especially hospitals' emergency teams' - preparedness to the test.
Natural events, including hurricanes, tornadoes, blizzards, and floods, as well as pre-planned terror attacks such as those that occurred on Sept. 11, 2001, have led to enormous numbers of casualties. Hospitals and health systems have been on the front lines to handle them all, but the federal government is looking to ensure that all healthcare facilities with a community are prepared to meet any possible future emergency challenges. (More)
The Benefits of Gene-based Medication Management - From Kristine Ashcraft
I wanted to be sure you knew that the precision medicine randomized controlled trial I mentioned in a prior meeting confirming the benefits of gene-based medication management just published - http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0170905.
Quick Summary: Researchers at Harding University in collaboration with Genelex and YouScript, conducted a randomized controlled trial in a high-risk population of chronically ill polypharmacy patients aged 50 years and older admitted to home health care after an inpatient hospitalization. The randomized controlled trial was designed to add pharmacogenetic data in an integrated clinical information system compared to a standard drug information system. The study revealed:
- 52 percent reduction in readmissions (p=0.007)
- 42 percent reduction in ER visits of (p=0.045)
- 85 percent decrease in mortality (p=0.05)
- $4,382 per patient potential cost savings in only 60-days based on Medicare average all-cause readmission and ED visit cost
These findings are a confirmation of previous studies (IMPACT) and a step toward preventing unnecessary hospital stays and other adverse effects in an already vulnerable population taking multiple medications.